1. Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis 
Sebastiano Nazzani, Felix Preisser, Marco Bandini, Michele Marchioni, Zhe Tian, Denis Soulières, Emanuele Montanari, Dario Ratti, Pietro Acquati, Alberto Briganti, Shahrokh F. Shariat, Firas Abdollah, Luca Carmignani, Pierre I. Karakiewicz 
European Urology Oncology 
Volume 1, Issue 4, Pages (September 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Smoothed 5-yr cumulative mortality estimates for patients affected by nonmetastatic reptroperitoneal sarcoma in (A) the overall population (n=1226), (B) patients aged <62 yr (n=618), and (C) patients aged ≥62 yr (n=608). DSM=disease-specific mortality; NDSM=non-DSM.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Smoothed 5-yr cumulative mortality estimates for patients affected by nonmetastatic reptroperitoneal sarcoma with (A) liposarcoma (n=800), (B) leiomyosarcoma (n=300), (C) low-grade disease (n=605), (D) high-grade disease (n=621), (E) tumor <17cm (n=610), (F) tumor ≥17cm (n=616), (G) radiation treatment (n=372), and (H) no radiation treatment (n=854). DSM=disease-specific mortality; NDSM=non-DSM.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions